A61K 51/0497
Conjugates with a carrier being an organic compounds
Official title: {conjugates with a carrier being an organic compounds}
A61K51/0497 (Conjugates with a carrier being an organic compounds) appears on 541 US grants and 945 published applications in this corpus.
Search patents in A61K- Granted patents
- 541
- Published applications
- 945
- Assignees
- 410
- Inventors
- 1,657
- Latest grant
- 6 Oct 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1976 | 1 | 0 |
| 1977 | 0 | 0 |
| 1978 | 0 | 0 |
| 1979 | 0 | 0 |
| 1980 | 1 | 0 |
| 1981 | 0 | 0 |
| 1982 | 0 | 0 |
| 1983 | 0 | 0 |
| 1984 | 3 | 0 |
| 1985 | 0 | 0 |
| 1986 | 0 | 0 |
| 1987 | 2 | 0 |
| 1988 | 0 | 0 |
| 1989 | 4 | 0 |
| 1990 | 2 | 0 |
| 1991 | 4 | 0 |
| 1992 | 5 | 0 |
| 1993 | 6 | 0 |
| 1994 | 4 | 0 |
| 1995 | 3 | 0 |
| 1996 | 3 | 0 |
| 1997 | 13 | 0 |
| 1998 | 18 | 0 |
| 1999 | 15 | 0 |
| 2000 | 11 | 0 |
| 2001 | 14 | 6 |
| 2002 | 11 | 15 |
| 2003 | 19 | 45 |
| 2004 | 13 | 23 |
| 2005 | 11 | 29 |
| 2006 | 19 | 18 |
| 2007 | 8 | 20 |
| 2008 | 17 | 20 |
| 2009 | 9 | 12 |
| 2010 | 9 | 14 |
| 2011 | 13 | 18 |
| 2012 | 10 | 14 |
| 2013 | 13 | 23 |
| 2014 | 14 | 20 |
| 2015 | 12 | 25 |
| 2016 | 14 | 23 |
| 2017 | 19 | 24 |
| 2018 | 16 | 24 |
| 2019 | 16 | 43 |
| 2020 | 24 | 58 |
| 2021 | 25 | 49 |
| 2022 | 20 | 78 |
| 2023 | 24 | 67 |
| 2024 | 33 | 92 |
| 2025 | 38 | 109 |
| 2026 | 25 | 76 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Near-infrared dyes and conjugates for targeting tumors6 Oct 2026US 12,752,023 B2Lahjavida, LLC
- Fibroblast activation protein inhibitor6 Oct 2026US 12,752,025 B2Boomray Pharmaceuticals Co., Ltd.
- DOTA-hapten compositions for anti-DOTA/anti-tumor antigen bispecific antibody pretargeted radioimmunotherapy25 Aug 2026US 12,714,758 B2Memorial Sloan Kettering Cancer Center
- PSMA-targeting conjugate and uses thereof4 Aug 2026US 12,697,404 B2Orano Med
- Anti-chitinase-3-like protein-1 (YKL-40) neutralizing antibody and uses thereof28 Jul 2026US 12,692,324 B2Institute of Nuclear Energy Research, Atomic Energy Council, Executive Yuan, R. O. C.
- Imaging methods and agents for grading and staging and subsequent treatment of prostate cancer in a patient24 Sep 2026US 2026/0284233 A1
- Radiolabeled fapi complex, and preparation method therefor and use thereof24 Sep 2026US 2026/0284237 A1Beijing Normal University
- Protease-activated receptor-2 (par2) targeted therapeutics and uses thereof24 Sep 2026US 2026/0284242 A1Radionetics Oncology, Inc.
- Complex comprising a psma-targeting compound linked to a lead or thorium radionuclide24 Sep 2026US 2026/0285887 A1Sciencons AS
- Trifunctional constructs with tunable pharmacokinetics useful in imaging and anti-tumor therapies17 Sep 2026US 2026/0273111 A1Cornell University
Most cited
By later US patents
- Method for enhancing transmembrane transport of exogenous molecules352US 5,416,016 APurdue Research Foundation · 1995
- Method for enhanced transmembrane transport of exogenous molecules302US 5,108,921 APurdue Research Foundation · 1992
- Method of local radiotherapy by polymerizing a material in vivo to form a hydrogel283US 5,942,209 AFocal, Inc. · 1999
- Water soluble paclitaxel prodrugs272US 5,977,163 APG-TXL Company, L. P. · 1999
- Nucleic acid hybridization assay and detectable molecules useful in such assay182US 4,707,440 AEnzo Biochem, Inc. · 1987